Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vestar Inc. deal

VSTR now has worldwide rights for AmBisome, excluding the U.S. and Canada, which Fujisawa

Read the full 145 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE